Genotyping of 836 thalassemia patients in
the United States by the National Institutes of Health Thalassemia
Clinical Research Network identified 106 (12.7%) with HbH
disease, 46 (5.5%) with a nondeletional mutation, and 44 with
HbH and Hb CS, most of them from the west coast.11